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ABSTRACT
Cytomegalovirus (CMV) infection is a major complication after allogeneic hematopoietic stem cell transplan-
tation (Allo-HSCT); however, we have little information on the clinical features of CMV reactivation after cord
blood transplantation using reduced-intensity regimens (RI-CBT) for adults. We reviewed medical records of
140 patients who underwent RI-CBT at Toranomon Hospital between January 2002 and March 2005. All the
patients were monitored for CMV-antigenemia weekly, and, if turned positive, received preemptive foscarnet
or ganciclovir. Seventy-seven patients developed positive antigenemia at a median onset of day 35 (range, 4-92)
after transplant. Median of the maximal number of CMV pp65-positive cells per 50,000 cells was 22 (range,
1-1806). CMV disease developed in 22 patients on a median of day 35 (range, 15-106); 21 had enterocolitis and
1 had adrenalitis. CMV antigenemia had not been detected in 2 patients, when CMV disease was diagnosed.
CMV disease was successfully treated using ganciclovir or foscarnet in 14 patients. The other 8 patients died
without improvement of CMV disease. In multivariate analysis, grade II-IV acute graft-versus-host disease was
a risk factor of CMV disease (relative risk 3.48, 95% confidential interval 1.47-8.23). CMV reactivation and
disease develop early after RI-CBT. CMV enterocolitis may be a common complication after RI-CBT.
© 2007 American Society for Blood and Marrow Transplantation
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cNTRODUCTION
Cord blood transplantation (CBT) is an attractive
lternative for patients with hematologic diseases who
ack a matched related or unrelated donor. The value
f CBT using myeloablative preparative regimens has
een conﬁrmed for pediatric patients [1,2]. Myeloab-
ative CBT for adult patients achieves engraftment in
0% of the patients, but carries a 50% risk of trans-
lant-related mortality (TRM), mostly resulting from
nfection [3,4]. We and other groups have reported
he feasibility of CBT using reduced-intensity regi- aens (RI-CBT) for adult patients with advanced he-
atologic diseases [5,6].
Because of delayed immune recovery and graft-
ersus-host disease (GVHD), infection is the leading
ause of TRM after CBT using myeloablative pre-
arative regimens [2-4,7]. However, studies on im-
une recovery following RI-CBT gave us hope that
I-CBT recipients may less frequently experience
VHD and infectious complications. Cytomegalovi-
us (CMV) has been 1 of the most feared infectious
omplications in CBT [8], as well as in conventional
llogeneic marrow or peripheral blood stem cell trans-
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T. Matsumura et al.578lantation (PBSCT) [9,10], although we have little
nformation on CMV infection following RI-CBT.
e investigated its frequency and clinical features in
atients who underwent RI-CBT for advanced hema-
ologic diseases.
ATIENTS AND METHODS
tudy Patients and Donors
We reviewed medical records of 140 patients who
nderwent RI-CBT at Toranomon Hospital between
anuary 2002 and March 2005. All the patients had
iseases that were incurable with conventional treat-
ents, and were considered inappropriate for conven-
ional allogeneic stem cell transplantation (allo-SCT)
ecause of the lack of an human leukocyte antigen
HLA)-identical sibling or a suitable related/unrelated
onor, aged 50 years old and/or organ dysfunction
generally attributable to previous intense chemother-
py and/or radiotherapy). All the patients provided
ritten informed consent in accordance with the re-
uirements of the institutional review board.
LA Typing and Donor Matching
An unrelated cord blood donor was searched
hrough the Japan Cord Blood Bank Network [11] for
atients without an HLA-identical sibling donor or a
uitable related/unrelated donor.
reparative Regimen
All the patients received purine analog-based pre-
arative regimens (Table 1).
ngraftment
Engraftment was deﬁned as white blood cell counts
1.0  109/L or absolute neutrophil counts 0.5
109/L for 2 consecutive days. Granulocyte-colony
timulating factor (G-CSF) was administered i.v. from
ay 1 until engraftment.
upportive Care and Management of
reengraftment Fever and GVHD
All the patients were managed in reverse isolation
n laminar airﬂow-equipped rooms, and received
rimethoprim/sulfamethoxazole for Pneumocystis ji-
oveci prophylaxis. Fluoroquinolone and ﬂuconazole
r itraconazole were administered for prophylaxis of
acterial and fungal infections, respectively. Prophy-
axis of herpes virus infection with acyclovir 600 mg/
ay was also given [12]. Neutropenic fever was man-
ged according to the guidelines [13].
Diagnosis and management of preengraftment im-
une reaction were reported previously [14]. GVHD
as clinically diagnosed in combination with skin or
ut biopsies after engraftment or attainment of 100% gonor chimerism. Acute (aGVHD) and chronic GVHD
cGVHD) were graded according to the established
riteria [15,16]. GVHD prophylaxis was a continuous
nfusion of cyclosporine 3 mg/kg or tacrolimus 0.03
g/kg from day 1 until the patients tolerated oral
dministration. It was tapered off from day 60 until
ay 150 or depending on the status of GVHD. If
rade II-IV aGVHD developed, 0.5-1.0 mg/kg/day of
rednisolone was added to cyclosporine or tacrolimus,
nd tapered from the beginning of clinical response.
anagement of CMV Infection
CMV-speciﬁc IgM antibodies in the cord blood
nits were not examined. Because most patients had
een heavily treated and received multiple transfu-
ions, anti-CMV antibodies were not examined before
ransplantation. Anti-CMV high-titer i.v. immuno-
able 1. Patient Characteristics
Variable Number
ge (median [range]) 55 (17-79)
ex (men/women) 81/59
rimary diseases
Acute lymphoblastic leukemia 19
Acute myeloid leukemia 44
Chronic myelogenous leukemia 5
Adult T cell leukemia 19
Myelodysplastic syndrome 14
Malignant lymphoma 29
Multiple myeloma 4
Aplastic anemia 6
isk of underlying diseases (high/low)* 99/41
reparative regimens
Flud 125 mg/m2  L-PAM (80 mg/m2)  TBI
(2-8 Gy) 121
Flud 125 mg/m2  L-PAM (140 mg/m2)  TBI
(4-8 Gy) 5
Flud 125 mg/m2  L-PAM (100 mg/m2)  TBI
(4-8 Gy) 2
Flud 150 mg/m2  BU 8 mg/kg  TBI
(4-8 Gy) 8
Flud 125 mg/m2  L-PAM (80-140 mg/m2) 2
Flud 150 mg/m2  BU 8 mg/kg 1
L-PAM 140 mg/m2 1
umber of infused mononuclear cells 10E7/kg
(median [range]) 2.7 (0.4-5.7)
umber of infused CD34 cells 10E5/kg
(median [range]) 0.73 (0.01-5.7)
LA antigen disparity 0/1/2/3 3/21/114/2
VHD prophylaxis
Cyclosporine 85
Tacrolimus 55
lud indicates ﬂudarabine; L-PAM, melphalan; BU, busulfan; TBI,
total body irradiation; GVHD, graft-versus-host disease.
Acute leukemia in complete remission, chronic myelocytic leuke-
mia in the chronic phase, malignant lymphoma in complete
remission, multiple myeloma in complete remission, myelodys-
plastic syndrome in refractory anemia (RA), and aplastic anemia
were deﬁned as low risk. All others were considered high risk.lobulin was not regularly administered. All packed
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CMV Infection following RI-CBT 579ed blood cells and platelets were transfused using
eukocyte-depleting ﬁlters.
CMV infection was deﬁned as isolation of CMV
r detection of viral proteins or nucleic acid in any
ody ﬂuid or tissue specimen. CMV disease was diag-
osed as follows: CMV enterocolitis was diagnosed by
astrointestinal symptoms with histologic demonstra-
ion of CMV on biopsy materials obtained by endos-
opy; CMV pneumonia was diagnosed when either a
ronchoalveolar lavage or a lung biopsy was positive
or CMV in a patient with characteristic signs, symp-
oms, and chest radiographic ﬁndings; CMV retinitis
as diagnosed by characteristic retinal opacities with-
ut other likely explanations for the retinal ﬁndings.
MV pp65 antigenemia was monitored weekly after
ngraftment or when patients died before engraft-
ent. Brieﬂy, 1.5  105 peripheral blood leukocytes
ere attached to slides using a cytocentrifuge and
xed with cold acetone. From 1/3 to 1/2 of the cen-
rifuged cells were ﬁxed on the slides. The cells were
ncubated with monoclonal antibody HRP-C7 (Tei-
in, Tokyo, Japan) raised against immediate-early an-
igen, and stained by the direct immunoperoxidase
ethod. These cells were analyzed under a light mi-
roscope and results were presented as the number of
ositive cells per 50,000 cells [17].
CMV antigenemia was managed according to the
eport by Kanda et al [17]. If CMV pp65-positive cells
xceeded 10/50,000, patients preemptively received
ither ganciclovir 5 mg/kg once daily or foscarnet 30
g/kg twice daily. Initiation of ganciclovir or foscar-
et with10 positive cells was optional in the patients
ho received more than 0.5 mg/kg of prednisolone.
he doses were adjusted for renal function [18]. Gan-
iclovir or foscarnet was discontinued when 2 consec-
tive results of CMV antigen were negative. When
MV disease was diagnosed during preemptive ther-
py, we increased the dose of ganciclovir to 5 mg/kg
wice a day, or foscarnet to 60 mg/kg twice or 3 times
aily.
ndpoints and Statistical Analysis
The aims of this study were (1) to determine the
ncidence of CMV infection after RI-CBT, (2) to
nvestigate its clinical features, and (3) to identify its
isk factors. The cumulative incidences of CMV dis-
ase and CMV reactivation deﬁned by the detection of
MV pp65 were evaluated using Gray’s method [19],
onsidering death without CMV reactivation as a
ompeting risk. Potential confounding factors consid-
red in the analysis were patient’s age, sex, stem cell
oses, HLA disparity, GVHD prophylaxis, condition-
ng regimens, and aGVHD. The inﬂuence of these
actors on the incidence of CMV disease and CMV
eactivation was evaluated with the proportional haz-
rd modeling treating the development of aGVHD Cnd the use of corticosteroids as time-dependent co-
ariates. Factors associated with at least borderline
igniﬁcance (P  .10) in the univariate analyses were
ubjected to a multivariate analysis using backward
tepwise proportional-hazard modeling. P-values of
.05 were considered statistically signiﬁcant.
ESULTS
atient’s Characteristics and Clinical Outcomes
Patient’s characteristics are shown in Table 1. Of
he 140 RI-CBT recipients, 112 patients (80%)
chieved primary engraftment on a median of day 20
range, 10-57). Sixty (43%) and 8 (6%) patients died of
ransplant-related causes and disease progression, re-
pectively, within 100 days of RI-CBT. Preengraft-
ent immune reaction [20] was diagnosed in 67 pa-
ients. Of the 112 patients who achieved engraftment,
7 (42%) developed grade II-IV aGVHD at a median
nset of day 25 (range, 13-94). Sixty-one patients
eceived prednisolone or methylprednisolone 0.5
g/kg/day within 100 days of RI-CBT because of
reengraftment immune reaction (n  26), engraft-
ent syndrome (n 3), aGVHD (n 16), and others
n 16). As of November 2005, the median follow-up
f the surviving patients was 13.0 months (range, 1.0-
0.7). Overall survival rates were 85% (95% conﬁ-
ence interval [CI]; 79-91%) and 53% (95% CI; 45-
2%) at days 30 and 100, respectively.
linical Features of CMV Reactivation
nd Diseases
Clinical features of CMV reactivation and diseases
re summarized in Table 2. CMV antigenemia was
ound in 77 patients (55%, 95% CI; 51-59%) on a
edian of day 35 (range, 4 to 92). Twenty-eight of
hose patients received prednisolone or methylpred-
isolone 0.5 mg/kg/day before development of
able 2. Clinical Features of CMV Reactivation and Disease
Variable
CMV reactivation
Number of patients
Onset (median [range])
Maximal levels of CMV antigenemia (range)
Preemptive therapy (ganciclovir/foscarnet/none)
CMV disease
Number of patients
Diagnose of CMV disease (median, [range])
Organ involvement
enterocolitis
pneumonia
retinitis
adrenalitis
Use of anti-CMV agents at the onset of CMV disease
(ganciclovir/foscarnet/none)MV indicates cytomegalovirus.
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T. Matsumura et al.580MV antigenemia. Forty-nine patients received fos-
arnet (n  41) or ganciclovir (n  8) preemptively.
nitial dose of ganciclovir was 5 mg/kg once daily. The
emaining 28 patients had not received foscarnet or
anciclovir according to our preemptive strategy, be-
ause of 10/50,000 of CMV pp65-positive cells.
Diagnosis of CMV disease was established in 22
atients (16%, 95% CI; 13-19%) on a median of day
3 (range 15-106); the diagnosis comprised enteroco-
itis (n  21) and adrenalitis (n  1). Of the 22
atients, 9 patients had received preemptive therapy
efore developing CMV disease. The remaining 13
atients had not received foscarnet or ganciclovir ac-
ording to our preemptive strategy, mostly because of
10/50,000 of CMV pp65-positive cells.
Diagnosis of CMV disease was established at post-
ortem examination in 1 patient. The other 21 pa-
ients were treated with either foscarnet or ganciclo-
ir. CMV disease was successfully treated in 14
atients. The remaining 8 patients died without im-
rovement of CMV disease, although CMV disease
as not the primary cause of death in any of these 8
atients.
isk Factors of CMV Antigenemia
nd CMV Disease
Risk factors of CMV reactivation and CMV dis-
ase were shown in Table 3 and Table 4, respectively.
D34-positive cell dose was signiﬁcantly associated
ith CMV reactivation on multivariate analysis (rela-
ive risk, 1.55; 95% CI 1.28-1.87; P  5.8  106).
able 3. Univariate and Multivariate Analyses for the Incidence of
MV Reactivation
Factor
Relative risk
(95% CI) P value
nivariate
Age 1.005 (0.989-1.021) .53
Sex 1.10 (0.71-1.72) .66
Disease status 0.68 (0.44-1.07) .098
Number of HLA mismatch 1.37 (0.80-2.36) .25
Number of infused
mononuclear cells 0.99 (0.68-1.45) .95
Number of infused CD34
cells 1.55 (1.28-1.87) 5.8  106
GVHD prophylaxis
(cyclosporine vs.
tacrolimus) 0.59 (0.37-0.94) .025
Preengraftment immune
reaction 1.14 (0.74-1.78) .55
Acute GVHD (grade II-IV) 1.21 (0.70-2.10) .49
Use of steroid* 1.64 (1.02-2.64) .042
ultivariate
Number of infused CD34
cells 1.55 (1.28-1.87) 5.8  106
MV indicates cytomegalovirus; CI, conﬁdence index; GVHD,
graft-versus-host disease.
Use of prednisolone or methyl-prednisolone 0.5 mg/kg/day.rade II-IV aGVHD was a risk factor of CMV disease *n multivariate analysis (relative risk, 3.48; 95% CI
.47-8.23; P  .0045).
ISCUSSION
The present study demonstrated that CMV infec-
ion is a signiﬁcant complication of RI-CBT. The
ncidence of CMV reactivation was 55% in our study,
hich was comparable with previous reports on RIST
21-23] and myeloablative bone marrow transplanta-
ion (BMT) and PBSCT [24,25]. In contrast, previ-
usly reported incidence of CMV reactivation after
BT (79%) [8] was higher than that of ours, although
t is the only previous report on CMV reactivation
fter CBT. The differences in preparative regimens
nd patient characteristics between the study [8] and
urs may have affected the incidence of CMV reacti-
ation. One of the unique ﬁndings in the present study
as that the timing of CMV reactivation after RI-
BT was earlier than that after RIST without in vivo
r ex vivo T cell depletion [21]. Another unique ﬁnd-
ng was the high incidence of CMV disease compared
ith transplantation of other stem cell sources
21,24,25]. Of the 77 patients with CMV antigenemia,
2 developed CMV disease in our study. The risk of
rogression from CMV reactivation to CMV disease
ay be high in CBT because of the intense immuno-
uppression [26].
The present study suggests that CMV infection is
ore likely to reactivate and to progress in RI-CBT
han in transplantation using other stem cell sources.
everal reasons can explain this hypothesis. First, the
reparative regimens including total body irradiation
TBI) in our study might have damaged recipient-
able 4. Univariate and Multivariate Analyses for the Incidence of
MV Disease
Factor
Relative risk
(95% CI) P value
nivariate
Age 1.021 (0.991-1.052) .16
Sex 1.15 (0.50-2.64) .74
Disease status 1.92 (0.65-5.64) .24
Number of HLA mismatch 2.54 (0.42-15.22) .31
Number of infused
mononuclear cells 0.59 (0.36-0.98) .041
Number of infused CD34 cells 1.34 (0.93-1.93) .11
GVHD prophylaxis
(cyclosporine vs. tacrolimus) 0.85 (0.36-1.99) .70
Preengraftment immune
reaction 0.76 (0.33-1.76) .52
Acute GVHD (grade II-IV) 3.48 (1.47-8.23) .0045
Use of steroid* 1.36 (0.53-3.48) .53
ultivariate
Acute GVHD (grade II-IV) 3.48 (1.47-8.23) .0045
MV indicates cytomegalovirus; CI, conﬁdence index; GVHD,
graft-versus-host disease.Use of prednisolone or methyl-prednisolone 0.5 mg/kg/day.
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CMV Infection following RI-CBT 581erived anti-CMV immune cells. That contrasts with
he report that recipient-derived T cells are associated
ith immune reaction against CMV early after trans-
lantation following preparative regimens without
BI [27]. The issue needs to be considered in deter-
ining preparative regimens for RI-CBT. Second,
ransplanted cord blood stem cells are immunologi-
ally naïve. Although anti-CMV cytotoxic T-lympho-
ytes in transplant grafts are considered to suppress
MV proliferation early after transplantation in CMV
eropositive recipients [28], passive immunity via
rafts against CMV cannot be expected in CBT, and
hus the risk of reactivation may be high. Third, post-
ransplant immune recovery is delayed in CBT. Little
s known about post-CBT immune recovery with only
ew reports. Although the numbers of T cells, B cells,
nd NK cells, and their in vitro reactivity after CBT
re comparable with those after BMT [29,30], post-
BT incidence of infections including CMV is high
2,7,8,31-35], and immune recovery is probably de-
ayed compared with BMT and PBSCT. Intense re-
ctivation itself can reportedly delay the recovery of
ellular immunity [36], which might be associated
ith the high incidence of CMV disease in the present
tudy. Finally, immunosuppression was intensiﬁed to
ontrol post-CBT immune reaction. In our study,
VHD prophylaxis was cyclosporine or tacrolimus
lone, which was mild compared with conventional
ransplantation. Immune reaction occasionally occurs
efore and at engraftment, requiring steroid treat-
ents [6,14,37]. In the present study, 62 patients re-
eived steroids within 100 days of CBT. Steroids
ight have suppressed the recovery of anti-CMV cy-
otoxic T-lymphocytes [38].
Some challenges remain to improve the manage-
ent of CMV reactivation after RI-CBT. First, opti-
al methods need to be established to monitor CMV
eactivation. We have introduced preemptive therapy
ased on the results of CMV antigenemia in our
ospital. The efﬁcacy of this method in PBSCT has
een reported [17], although it might not be applica-
le to CBT. Of the 22 patients with CMV disease, 9
rogressed from CMV antigenemia to disease despite
reemptive therapy. CMV disease developed with less
han 10/50,000 pp65-positive cells in 13 patients.
hese observations suggest that antiviral therapy
ight be necessary immediately after CMV antigen-
mia is detected in CBT. More sensitive diagnostic
ests such as genetic examinations [39] are also helpful
n early detection of CMV reactivation. Second, the
ptimal preemptive strategy that is applicable to CBT
as to be established. Because the disease rate in the
ntreated CMV positives was 46%, preemptive ad-
inistration of anti-CMV agents might be required
or patients with 10/50,000 pp65-positive cells. Al-
ernatively, universal prophylaxis of CMV might be
orth investigating. Optimal dose of preemptive gan- siclovir and foscarnet must be also investigated. We
educed doses of preemptive foscarnet and ganciclovir
ostly because of concerns of its renal toxicity and
yelotoxicity, respectively. However, the failure rate
f preemptive ganciclovir or foscarnet was 18%, and it
as higher than that in the studies in which those were
ot reduced [40,41]. Clinical impact of the dose of
anciclovir or foscarnet on preemptive therapy should
e investigated in future clinical studies. Finally, iden-
iﬁcation of high-risk group for CMV reactivation is
ecessary. The reported risk factors in conventional
SCT include GVHD, steroid administration, CMV
erostatus of recipients and donors, and age [22,28,42-
4]. The high dose of transfused CD34-positive cells
as an independent risk factor for CMV reactivation
n our analysis (Table 3). The association between the
umber of CD34-positive cells and CMV infection
as not been reported in previous studies on BMT
nd PBSCT. It remains unknown and awaits further
nvestigations. aGVHD was an independent risk fac-
or for CMV disease. This is comparable with the
eport on CMV disease after allo-SCT [25].
Most of the patients with CMV disease had CMV
nterocolitis in the present study. None developed
MV pneumonia or retinitis. Although the reason for
he high incidence of gastrointestinal CMV disease
fter RI-CBT remains unclear, the use of TBI and
elphalan in the preparative regimens that have sig-
iﬁcant gastrointestinal mucous toxicity [45] and com-
lications of gut GVHD and thrombotic microangi-
pathy [14] may be related. Although there are
ifferent opinions on the usefulness of antigenemia in
iagnosing CMV enterocolitis [46-48], the present
tudy demonstrated that monitoring CMV antigen-
mia can play a certain role in early diagnosis of CMV
nterocolitis after RI-CBT. Further studies are nec-
ssary to demonstrate the pathogenesis of gastrointes-
inal CMV disease after RI-CBT and to develop di-
gnostic methods for its early detection.
Although the present study provided novel infor-
ation on CMV infection after RI-CBT, some issues
emain to be investigated. First, the present study was
etrospective and small sized. Prospective, large-sized
tudies are awaited. Second, RI-CBT recipients are
ikely to have potential organ dysfunction because
ost of them are at advanced ages and have been
eavy treated with chemotherapies. Such characteris-
ics of patients may affect the treatment of CMV
nfection. Pharmacokinetics of antiviral agents in
lder patients has not been well investigated, requir-
ng further studies. Third, recipient pretransplant
MV serostatus was reported to correlate with mor-
ality after CBT [49]. However, anti-CMV antibodies
ere not examined before transplantation in this study
ecause most patients had been heavily treated and
eceived multiple transfusions. Pretransplant CMV
erostatus needs to be investigated in future studies.
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T. Matsumura et al.582ourth, day 100 mortality was 49% in the present
tudy. It is higher than that in the previous study
eported by the Minnesota group [5]. The exact rea-
on of these differences remains unknown; however, it
ight be partly from the difference in patient’s back-
rounds between these studies. This high mortality
ate and patient’s backgrounds in the present study
ight have affected the results. Fifth, the management
f CMV infection in the present study might have
ffected the incidence of CMV disease; we used the
educed dose of foscarnet or ganciclovir and anti-
MV high-titer i.v. immunoglobulin was not regularly
dministered. Finally, late CMV infection remains to be
nvestigated. Because CMV antigenemia-guided pre-
mptive strategy has been established [50], the progno-
is of CMV infection following BMT and PBSCT
mproved; however, late CMV disease remains a sig-
iﬁcant issue [51]. The observation period was short
n the present study, and could not provide enough
nformation on late CMV disease.
The present study demonstrated that CMV infec-
ion is a signiﬁcant complication of RI-CBT. Al-
hough RI-CBT is an attractive alternative, physicians
hould be alert to the fact that this transplant proce-
ure is associated with a high risk of CMV infection.
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